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RBPJ Mutations Identified in Two Families
Affected by Adams-Oliver Syndrome
Susan J. Hassed,1,5,* Graham B. Wiley,2,5 Shaofeng Wang,2,5 Ji-Yun Lee,4 Shibo Li,1,3 Weihong Xu,1
Zhizhuang J. Zhao,3 John J. Mulvihill,1 James Robertson,2 James Warner,3 and Patrick M. Gaffney2,*
Through exome resequencing, we identified two unique mutations in recombination signal binding protein for immunoglobulin
kappa J (RBPJ) in two independent families affected by Adams-Oliver syndrome (AOS), a rare multiple-malformation disorder consisting
primarily of aplasia cutis congenita of the vertex scalp and transverse terminal limb defects. These identified mutations link RBPJ, the
primary transcriptional regulator for the Notch pathway, with AOS, a human genetic disorder. Functional assays confirmed impaired
DNA binding of mutated RBPJ, placing it among other notch-pathway proteins altered in human genetic syndromes.Signaling through the Notch pathway regulates cell prolif-
eration, death, differentiation, and acquisition of specific
fates in a context-dependent manner.1 Aberrant gain or
loss of function of notch-signaling components has been
implicated in human disease. Mutations in notch1 ligand
JAG1 (MIM 601920) and notch2 receptor NOTCH2 (MIM
600275) cause Alagille syndrome types 1 (ALGS1 [MIM
118450]) and 2 (ALGS2 [MIM 610205]), respectively.2
Mutations in JAG1 can also lead to tetralogy of Fallot3
(TOF [MIM 187500]), whereas mutations in NOTCH3
(MIM 600276) can result in cerebral autosomal-dominant
arteriopathy with subcortical infarcts and leukoencephal-
opathy (CADASIL [MIM 125310]).1
Notch signaling induces cleavage of the Notch intracel-
lular domain (NICD), which translocates to the nucleus
and combines with RBPJ to form a transcriptional com-
plex. RBPJ, the principal DNA-binding partner of the
NICD, is an evolutionarily conserved protein that coor-
dinates transcriptional activation of Notch-target genes
through the assembly of protein complexes containing
coactivators. To date, there are no germline RPBJ (MIM
147183) mutations reported to cause a genetic disorder
in humans.
Adams-Oliver syndrome (AOS [MIM 100300]) was first
described as the combination of vertex scalp defects and
terminal limb defects.4 The clinical features are highly vari-
able in both anatomic site and severity of expression. The
most common defects are terminal limbmalformations (in
84% of cases), including osseous syndactyly, rudimentary
bones, or completely absent digits. Congenital cutis
aplasia, the second-most-common defect (in 75% of cases),
usually occurs over the posterior parietal region. Under-
lying bone defects can be present, and tortuous veins can
occur on the posterior scalp.5,6 Congenital heart defects,
microcephaly, esotropia, microphthalmia, cleft lip with
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The Americnipples, an imperforate vaginal hymen, developmental
delay, and various digital anomalies are frequent.4,5 AOS
usually shows autosomal-dominant inheritance;4,5,7–9
however, sporadic cases and families appearing autosomal
recessive are known.10–12
The AOS-affected individuals in our study belong to one
of two families; family 1 was diagnosed by us, and family 2
was diagnosed by our review of medical records and photo-
graphs (Figure 1A). In family 1, the proband (individual
III-1) was identified at birth to have cutis aplasia. Her
extremities showed syndactyly of her second and third
toes and were otherwise normal. She has microcephaly
and short palpebral fissures. She was mildly delayed in
gross motor milestones. Her father (II-2) has short distal
phalanges of his fingers and has absent toes and short
metatarsals bilaterally. He has microcephaly, intellectual
deficits, and is at the borderline of mildmental retardation.
Neither individual has heart defects, immune defects, cutis
marmorata, or other associated abnormalities.
In family 2, individual II-1 has normal intelligence and
mild limb reductions of his hands (Figure 1B). Individual
II-3 has shortened distal phalanges of her left hand, bilat-
eral reduction of her toes, and normal intelligence. Indi-
vidual III-3 has a large scarred area that is the result of cutis
aplasia at birth, asymmetric shortening of the hands bilat-
erally, asymmetric reductions of the feet, and intellectual
deficits. Individual III-4 is mildly affected with fifth-finger
nail hypoplasia, fifth-toe shortening, and normal develop-
ment. There is no report of congenital heart defects, other
associated anomalies, or immune defects in the family.
To identify AOS-causing mutations, we performed
exome resequencing by using a variant-filtering strategy.
After informed consent was obtained (protocol 09567
from the institutional review board at the University of
Oklahoma Health Sciences Center), blood samples were
drawn from all participants and DNA was isolated fromUniversity of Oklahoma Children’s Physicians Building, 1200 Children’s
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Figure 1. Pedigree Structure and Clinical Features of Families
(A) Pedigrees exhibiting autosomal-dominant inheritance of AOS
and deleterious mutation of RBPJ. Individuals who were tested
via exome sequencing are designated with an asterisk. Arrows
point to the index cases in each family.
(B) Photographs of features diagnostic for AOS in family 2. The top
row shows the hands and foot of subject II-3. The second row
shows the cutis aplasia scar, hands, and feet of subject III-3.six affected individuals and one unaffected first-degree
family member in each of the two unrelated families.
Exome enrichment was performed with the TruSeq Exome
Enrichment Kit (Illumina, San Diego, CA) as per the manu-
facturer’s protocol. Sequencing was performed on an Illu-
mina HiSeq 2000 instrument with paired-end 100 bp
reads. Sequence reads were mapped to the human refer-
ence genome (hg18) with the Burrows-Wheeler Aligner
(BWA).13 Local realignment around problematic areas
and empirical base-quality-score recalibration were done
with the Genome Analysis Tool Kit (GATK).14 SNPs were
identified with the GATK Unified Genotyper. VariantsTable 1. Gene-Filtering Strategy Used for Identifying RBPJ in AOS Ped
Number of genes with R1 nsSNP
From row 1, number of genes with R1 nsSNP evolutionarily conserveda
From row 2, number of genes not in 1000 Genomes Project
From row 3, number of genes not in dbSNP130
From row 4, number of genes shared in AOS within pedigree
From row 5, number of genes shared in AOS between pedigrees
The following abbreviations are used: nsSNP, nonsynonymous SNP; and AOS, Ad
aEvolutionary conservation was determined by comparison to PhastCon 44 verte
392 The American Journal of Human Genetics 91, 391–395, August 1were excluded from further analyses if they failed to
meet any of the following parameters: an alignment
quality higher than 30, a read depth of at least 8,
a quality-by-depth score greater than 2.5, presence within
a homopolymer run of 5 bases or fewer, a strand-bias score
less than 10.0, and a map-quality score greater than 25.
We used Annovar to functionally annotate variants prior
to filtering.15 We screened variants to first remove synony-
mous variants and then to remove variants within seg-
mental duplications and variants outside highly conserved
regions. Variants previously seen in the 1000 Genomes
Project and the dbSNP130 variant database were removed.
Remaining variants were then mapped back to their
respective genes. Lists of these genes were assembled for
each sample on the basis of a dominant or recessive model;
the dominant model required only one variant per gene,
and the recessive model required two or more variants
per gene. Because AOS is a rare condition and was ex-
pressed in multiple generations in both families, the domi-
nant model was considered most plausible. Lists of genes
by individual within each family were compared to those
of other members of their respective family for the identi-
fication of family-wide, nonsynonymous variants that
appeared to segregate with AOS affectation status (Tables
S1 and S2, available online). We identified 44 genes with
mutations unique to AOS-affected individuals in family 1
and 26 genes in family 2. The gene lists from each family
were compared, which identified only one gene in com-
mon, RBPJ (RefSeq accession number NM_005349)
(Table 1). The raw alignment of reads covering the respec-
tive variants for each individual was then inspected with
the Integrated Genome Viewer and determined to be suffi-
cient for the variant call.16 We then confirmed the pres-
ence of the mutations in each individual by using Sanger
sequencing (Figure S1).
In family 1, the RBPJ mutation, an A to G transition
(c.188A>G) (RefSeq NM_005349.2), resulted in a hetero-
zygous glutamic acid to glycine amino acid change
(p.Glu63Gly) (RefSeq NM_005349). The mutation in
family 2 was an A to G transition (c.505A>G) (RefSeq
NM_005349.2) aswell and resulted in aheterozygous lysineigrees
Family 1 Family 2
II-2 II-3 III-1 II-1 II-3 III-3 III-4
6,072 5,903 6,069 5,817 6,007 5,895 5,273
2,613 2,497 2,616 2,496 2,568 2,531 2,213
329 316 335 309 314 303 279
187 177 183 180 187 167 173
44   26   
1 (RBPJ)      
ams-Oliver syndrome.
brate data.
0, 2012
Figure 2. Functional Characterization of RBPJ Alterations Identi-
fied in AOS-Affected Families
(A) A representative EMSA from three independent experiments.
The first lane shows a free probe derived from the HES1 promoter;
subsequent lanes show nuclear protein extract (20 ng and 10 ng)
that was prepared either from HEK 293T cells transfected with
FLAG-tagged wild-type or mutant RBPJ or from untransfected
HEK 293T cells as indicated. The shifted band corresponding to re-
combinant RBPJ constructs is labeled with an arrow. Super shift
was performed by the addition of an antibody to the FLAG epitope
expressed on the recombinant RBPJ proteins and is labeled in the
figure as ‘‘SS.’’ A nonspecific band is labeled ‘‘NS.’’
(B) We performed densitometric quantification of the EMSA bands
from four independent experiments. The mean densities from un-
transfected HEK 293T cells and HEK 293T cells transfected with
various RBPJ constructs are shown in the columns. Error bars repre-
sent themean5 standarderrorof themean (SEM). Statistical differ-
ences between the means were calculated with the unpaired t test.
(C) ChIP was performed with anti-FLAG and anti-isotype control
IgG on chromatin prepared from HEK 293T cells transfected
with RBPJ constructs. Quantification of enriched DNA fragments
was performed with quantitative RT-PCR with primers flanking
a known RBPJ binding site in theHES1 promoter. Shown is a repre-
sentative ChIP-qPCR from two independent experiments. Each
experiment was composed of three technical replicates. Mean
enrichment as a percentage of input chromatin is displayed. Error
bars correspond to the mean5 SEM.to glutamic acid amino acid change (p.Lys169Glu) (RefSeq
NM_005349) (Figure S2). Comparison of the human RBPJ
amino acid sequence with the highly conserved homolo-
gous CSL protein from C. elegans located both muta-
tions in the DNA-binding domain (Figure S3).17 The
amino acid positions are either within two positions of
(p.Glu63Gly) or adjacent to (p.Lys169Glu) amino acids
that interact directly with bound DNA (Figure S2), and
both were predicted to be damaging by SIFT18 and
Polyphen2.19The AmericGiven the location of the mutations in each family, we
hypothesized that the mutated forms of RBPJ would
demonstrate defects in DNA binding. To test this hypoth-
esis, we made FLAG-tagged expression constructs contain-
ing wild-type RBPJ or the two mutated forms (Table S3 and
Figure S4) and performed an electrophoretic mobility shift
assay (EMSA) with an oligonucleotide corresponding to
a canonical RBPJ binding site in the promoter of human
homolog of hairy and enhancer of split 1 (Drosophila),
HES1 (MIM 139605) (Table S4). Wild-type RBPJ formed
a specific complex with the probe in an amount propor-
tional to that of nuclear extract used (Figure 2A). In con-
trast, compared with the negative control, both mutant
forms (p.Glu63Gly and p.Lys169Glu) did not exhibit any
specific binding complex. Densitometric measurement of
band intensity from multiple independent experiments
showed statistically significant differences between wild-
type RBPJ and mutants of RBPJ (Figure 2B). Using a super-
shift assay with anti-FLAG tag antibody, we verified that
recombinant RBPJ bound to the HES1 probe was present
in the shifted protein complex (Figure 2A). Binding speci-
ficity of RBPJ to the HES1 sequence was confirmed by
cold competition (Figure S5).
To determine whether these mutations affect the inter-
action between RBPJ and the endogenous HES1 promoter
in live cells, we examined RBPJ binding by chromatin
immunoprecipitation (ChIP) quantitative PCR (qPCR) in
cells expressing similar levels of recombinant wild-type
RBPJ and mutants (Figure S6 and Table S5). Compared
with wild-type RPBJ, RBPJ mutants showed decreased
binding to the HES1 promoter (Figure 2C). The qPCR
product was verified by Sanger sequencing to be the target
sequence from the HES1 promoter (data not shown). The
reduced binding affinity of RBPJ mutants also resulted in
decreased expression of HES1 (Figure S7).
To evaluate whether mutations in RBPJ affect protein in-
teraction with the NICD, we cotransfected human em-
bryonic kidney (HEK) 293T cell lines with NICD and
RBPJ constructs. Coimmunoprecipitation (Co-IP) con-
firmed that neither of the RBPJ mutations altered
protein-protein interaction with NICD given that similar
amounts of RBPJ and NICD were detected in each sample
(Figure S8).
In this study, we have identified two mutations in RPBJ,
the key transcriptional regulator for Notch, in two inde-
pendent kindreds affected by AOS. These mutations are
located in highly conserved protein regions that are pre-
dicted to make contact with DNA. Functional studies
confirmed that both mutations reduce the affinity of
RBPJ binding to a canonical sequence in the HES1 pro-
moter. A previous site-directed mutagenesis screen of
RBPJ identified two lysine residues that are directly adja-
cent to p.Lys169Glu and that are important for DNA
binding, supporting our findings.20
A link between Notch and AOS had been previously
hypothesized on the basis of the association between car-
diovascular malformations and aplasia cutis congenital.21an Journal of Human Genetics 91, 391–395, August 10, 2012 393
RBPJ-mediated NOTCH signaling is important for mesen-
chymal cell proliferation and skeletal formation,22
epidermis and hair-follicle development,23 and vascular-
structure formation.24 Furthermore, RBPJ-deficient mice
have defective cranial-bone formation,25 and RBPJ-
conditional-knockout mice have arteriovenous malforma-
tions.26 These findings inmodel systemsoverlap thepheno-
typic spectrum of AOS.
Mutations in ARHGAP31 (MIM 610911) and DOCK6
(MIM 614194) have been reported in AOS-affected
kindreds with both autosomal-dominant and autosomal-
recessive inheritance.9,10 The mechanism by which these
genes influence AOS has been reported to be through
inactivation of Rac1 and Cdc42; inactivation of these
proteins leads to impaired cytoskeletal homeostasis.9,10
Our discovery of mutations in RBPJ adds to the genetic
heterogeneity of AOS and underscores the hypothesis
that AOS is a multigene, multipathway disorder. It is
tempting to postulate that these genes converge on a final
common pathway that results in the manifestations of
AOS; however, existing data are insufficient for drawing
this conclusion at this time. No deleterious mutations in
ARHGAP31 or DOCK6 were found in our AOS-affected
families.
In summary, our data provide genetic evidence that
alterations in the Notch transcription factor RBPJ predis-
pose to malformations in humans. Given the phenotypic
heterogeneity of AOS, our results support RBPJmutational
screening for individuals presenting with congenital mal-
formations consistent with AOS and related disorders.Supplemental Data
Supplemental Data include eight figures and five tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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